title: Isolated chloroma: the effect of early antileukemic therapy.
abstract: OBJECTIVE
  To evaluate the effect of antileukemic chemotherapy administered at diagnosis on the survival of patients with isolated chloroma.
  
  
  METHODS
  Retrospective review of locally identified patients and analysis of cases from the medical literature.
  
  
  METHODS
  The records of all patients with isolated chloroma identified at three teaching hospitals in Toronto between 1980 and 1994 were reviewed. A MEDLINE search was done to identify all cases of isolated chloroma reported in the English-language medical literature. Patients with a previous known hematologic disorder were excluded.
  
  
  METHODS
  The effect of therapy on 1) the interval between diagnosis of chloroma and diagnosis of acute myeloid leukemia and 2) survival was determined.
  
  
  RESULTS
  7 local patients and 83 published cases were identified, for a total of 90 evaluable patients. For the entire group, the median time to the diagnosis of acute myeloid leukemia was 9 months, and median survival was 22 months. Chemotherapy was administered to 49 patients (54%) at diagnosis of chloroma. Significantly fewer patients treated with chemotherapy subsequently developed acute myeloid leukemia (41% compared with 71%; P = 0.001). Survival was longer in patients treated with chemotherapy (> 50% alive with a median follow-up of 25 months compared with a median survival of 13 months for those initially untreated; P = 0.001). Multivariate analysis showed that neither local radiotherapy nor surgery had an effect on survival.
  
  
  CONCLUSIONS
  Administration of antileukemic chemotherapy at diagnosis of chloroma is associated with a significantly lower probability of developing acute myeloid leukemia and with longer survival.
authors.affiliation: Toronto Hospital and Princess Margaret Hospital, Canada.
authors.forename: K R
authors.initials: KR
authors.lastname: Imrie
authors.forename: M J
authors.initials: MJ
authors.lastname: Kovacs
authors.forename: D
authors.initials: D
authors.lastname: Selby
authors.forename: J
authors.initials: J
authors.lastname: Lipton
authors.forename: B J
authors.initials: BJ
authors.lastname: Patterson
authors.forename: D
authors.initials: D
authors.lastname: Pantalony
authors.forename: P
authors.initials: P
authors.lastname: Poldre
authors.forename: B Y
authors.initials: BY
authors.lastname: Ngan
authors.forename: A
authors.initials: A
authors.lastname: Keating
mesh_terms: D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012044:Regression Analysis; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents